Top

Published in:

01-04-2007

Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases

Authors: Kuniya Tanaka, MD, PhD, Hiroshi Shimada, MD, PhD, Michio Ueda, MD, Kenichi Matsuo, MD, Itaru Endo, MD, PhD, Shinji Togo, MD, PhD

Published in: Annals of Surgical Oncology | Issue 4/2007

Abstract

Background

We investigated factors affecting 5-year survival in patients undergoing hepatic resection for colorectal cancer metastases, including events long after initial hepatectomy. Although retrospective studies have demonstrated survival benefit of hepatectomy for metastatic colorectal cancer, few have included sufficient 5-year survivors to identify survival-related factors throughout the clinical course.

Methods

We divided 156 patients with hepatectomy for colorectal cancer metastases into 5-year survivors (n = 64) and patients dying before 5 years after hepatectomy (n = 92). Clinicopathologic data were compared retrospectively with respect to long-term outcome.

Results

By multivariate analysis, large liver tumors (adjusted relative risk, 2.029; P = .011), short tumor doubling time (1.809; P = .026), and origin from poorly differentiated primary adenocarcinoma (12.632; P = .001) compromised survival, whereas initial treatment-related variables did not. Although no difference was seen in initial treatment-related variables between 5-year survivors with recurrence after hepatectomy and patients dying before 5 years, repeat surgery was used more frequently in survivors (P < .001), typically with adjuvant chemotherapy.

Conclusions

Reoperations for each recurrence of metastases, followed by additional chemotherapy, frequently resulted in long survival.

Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of indications for resection. Surgery 1988;103:278–88

Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef

Nordlinger B, Guiguet M, Vaillant JC, et al. Association Francaise de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77:1254–62PubMedCrossRef

Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938–46PubMed

Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231:487–99PubMedCrossRef

Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery 1994; 116:703–11PubMed

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–21PubMedCrossRef

Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997; 84:977–80PubMedCrossRef

Sugawara Y, Yamamoto J, Yamasaki S, Shimada K, Kosuge T, Makuuchi M. Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery 2001; 129:408–13PubMed

10.

Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278–84PubMed

11.

Scheele J, Stangl R, Altendorf-Hofmann A, Gall F. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110:13–29PubMed

12.

Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Ann Surg 1987; 205:264–70PubMedCrossRef

13.

Stone MD, Cady B, Jenkins RL, McDermott WV, Steele GD Jr. Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 1990; 125:718–22PubMed

14.

Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225:51–60PubMedCrossRef

15.

Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Moriya Y, Sugihara K. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178:275–81PubMedCrossRef

16.

Suzuki S, Sakaguchi T, Yokoi Y, et al. Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129:421–8PubMed

17.

Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases. The third hepatectomy. Ann Surg 2003; 238:871–84PubMedCrossRef

18.

Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88:980–5PubMedCrossRef

19.

Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–22PubMedCrossRef

20.

Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232:777–85PubMedCrossRef

21.

Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–9PubMedCrossRef

22.

Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001; 8:347–53PubMedCrossRef

23.

Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30PubMedCrossRef

24.

Yamanaka N, Okamoto E, Oriyama T, et al. A prediction scoring system to select the surgical treatment of liver cancer: further refinement based on 10 years of use. Ann Surg 1994; 219:342–6PubMedCrossRef

25.

Terminology Committee of the International Hepato-Pancreato-Biliary Association. Brisbane 2000 terminology of liver anatomy and resection. HPB 2000; 2:333–9

26.

Couinaud C. Lobes et segments hépatiques: notes sur l’architecture anatomique et chirurgicale du foie. Presse Med 1954; 62:709–12PubMed

27.

Healey JE, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts. Arch Surg 1953; 66:599–616

28.

Collins VP, Loeffier RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol 1956; 76:988–1000

29.

Staab HJ, Anderer FA, Hornung A, Stumpf E, Fischer R. Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982; 46:773–81PubMed

30.

Havelaar IJ, Sugerbaker PH, Vermes M, Miller DL. Rate of growth of intraabdominal metastases from colorectal cancer. Cancer 1984; 54:163–71PubMedCrossRef

31.

Fujii S. Hepatic metastases development from colorectal cancer in view of CEA doubling time. Yokohama Igaku 1994; 45:627–35 (in Japanese with English abstract)

32.

Shimada H, Nanko M, Fujii S, et al. Treatment strategies for hepatic metastasis from colorectal cancer. J Hepatobiliary Pancreat Surg 1995; 2:116–21CrossRef

33.

Watine J, Miédougé M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases. Dis Colon Rectum 2001; 44:1791–9PubMedCrossRef

34.

Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992; 216:493–504PubMedCrossRef

35.

Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647–51PubMed

36.

Koga H, Moriya Y, Akasu T, Fujita S. The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Eur J Surg Oncol 1999; 25:292–6PubMedCrossRef

37.

Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling time: the most important pre-hepatectomy predictor of survival and non-recurrence in hepatic colorectal cancer metastasis. World J Surg 2004; 28:263–70PubMedCrossRef

38.

Lorenz M, Müller H, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998; 228:756–64PubMedCrossRef

39.

Onaitis M, Morse M, Hurwitz H, et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg 2003; 237:782–9PubMedCrossRef

40.

Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039–48PubMedCrossRef

41.

Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395–403PubMedCrossRef

42.

Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004; 78:238–44PubMedCrossRef

43.

Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007–13PubMedCrossRef

44.

Ekberg H, Tranberg KG, Andersson R, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11:541–7PubMedCrossRef

45.

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759–66PubMedCrossRef

46.

Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–47PubMedCrossRef

47.

Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systemic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531–5

48.

De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed

49.

Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905–14PubMedCrossRef

50.

Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041–7PubMedCrossRef

51.

Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000–5PubMedCrossRef

52.

Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501–18PubMed

53.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60–5PubMedCrossRef

54.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef

55.

Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45PubMedCrossRef

Title: Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases
Authors: Kuniya Tanaka, MD, PhD
Hiroshi Shimada, MD, PhD
Michio Ueda, MD
Kenichi Matsuo, MD
Itaru Endo, MD, PhD
Shinji Togo, MD, PhD
Publication date: 01-04-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 4/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9071-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2007

Extrapleural Pneumonectomy Is the Preferred Surgical Management in the Multimodality Therapy of Pleural Mesothelioma: Con Argument

Antitumor Effect of Gemcitabine on Orthotopically Inoculated Human Gallbladder Cancer Cells in Nude Mice

Laparoscopic Pelvic Autonomic Nerve-Preserving Surgery for Patients with Lower Rectal Cancer after Chemoradiation Therapy

Trends in the Treatment and Outcome of Pancreatic Cancer in the United States

In Vivo Intraoperative Radiotherapy: A Novel Approach to Radiotherapy for Early Stage Breast Cancer

Controversies in Surgical Oncology: Routine Anthracycline-based Adjuvant Chemotherapy for Stage III Extremity Soft Tissue Sarcoma